Navicixizumab
Modify Date: 2024-04-06 18:28:44
Navicixizumab structure
|
Common Name | Navicixizumab | ||
|---|---|---|---|---|
| CAS Number | 1638338-43-8 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of NavicixizumabNavicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer[1][2][3]. |
| Name | Navicixizumab |
|---|
| Description | Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
IC50: hVEGF (0.36 nM), mVEGF (25.5 nM), hDLL4 (1.3 nM) |
| In Vitro | Navicixizumab (0-100 μM) 在 hVEGF 存在的情况下减少人内皮细胞的增殖[3]. |
| In Vivo | Navicixizumab (15 mg/kg，每周一次，持续 4 周) 抑制结肠异种移植肿瘤的生长[3]。 |
| References |
| No Any Chemical & Physical Properties |